International Journal of Molecular Sciences Cancer's Achilles' Heel: Apoptosis and Necroptosis to the Rescue

Apoptosis, and the more recently discovered necroptosis, are two avenues of programmed cell death. Cancer cells survive by evading these two programs, driven by oncogenes and tumor suppressor genes. While traditional therapy using small molecular inhibitors and chemotherapy are continuously being utilized, a new and exciting approach is actively underway by identifying and using synergistic relationship between driver and rescue genes in a cancer cell. Through these synthetic lethal relationships, we are gaining tremendous insights into tumor vulnerabilities and specific molecular avenues for induction of programmed cell death. In this review, we briefly discuss the two cell death processes and cite examples of such synergistic manipulations for therapeutic purposes.

[1]  Ping Wang,et al.  Necroptosis in tumorigenesis, activation of anti-tumor immunity, and cancer therapy , 2016, Oncotarget.

[2]  G. Ichim,et al.  A fate worse than death: apoptosis as an oncogenic process , 2016, Nature Reviews Cancer.

[3]  M. MacFarlane,et al.  Targeting cell death signalling in cancer: minimising ‘Collateral damage' , 2016, British Journal of Cancer.

[4]  Jian Yu,et al.  Necroptosis: an alternative cell death program defending against cancer. , 2016, Biochimica et biophysica acta.

[5]  Mariko Sasaki,et al.  Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression. , 2016, Cancer discovery.

[6]  Z. Yang,et al.  Cancer therapy in the necroptosis era , 2016, Cell Death and Differentiation.

[7]  Li Jin,et al.  CaMKII is a RIP3 substrate mediating ischemia- and oxidative stress–induced myocardial necroptosis , 2016, Nature Medicine.

[8]  T. Bivona,et al.  The Hippo effector YAP regulates the response of cancer cells to MAPK pathway inhibitors , 2016, Molecular & cellular oncology.

[9]  Amy McKee,et al.  Successes and Challenges of PARP Inhibitors in Cancer Therapy , 2015, Front. Oncol..

[10]  Liang Zhao,et al.  FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy , 2015, Clinical Cancer Research.

[11]  I. Rivens,et al.  A study of thermal dose-induced autophagy, apoptosis and necroptosis in colon cancer cells , 2015, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[12]  A. Trumpp,et al.  A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer , 2015, Cell.

[13]  Francesca M Buffa,et al.  Hypoxia-induced p53 modulates both apoptosis and radiosensitivity via AKT. , 2015, The Journal of clinical investigation.

[14]  R. Bohle,et al.  RIPK3 expression in cervical cancer cells is required for PolyIC-induced necroptosis, IL-1α release, and efficient paracrine dendritic cell activation , 2015, Oncotarget.

[15]  M. Erlacher,et al.  How cell death shapes cancer , 2015, Cell Death and Disease.

[16]  R. Majeti,et al.  Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia , 2015, Nature Medicine.

[17]  P. Vandenabeele,et al.  Necroptosis and its role in inflammation , 2015, Nature.

[18]  T. Vanden Berghe,et al.  Necroptosis, in vivo detection in experimental disease models. , 2014, Seminars in cell & developmental biology.

[19]  S. Fesik,et al.  Drugging the undruggable RAS: Mission Possible? , 2014, Nature Reviews Drug Discovery.

[20]  R. Bernards,et al.  RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells. , 2014, Cell reports.

[21]  H. Ogiwara,et al.  Proposal for a synthetic lethality therapy using the paralog dependence of cancer cells--response. , 2014, Cancer research.

[22]  Eytan Ruppin,et al.  Predicting Cancer-Specific Vulnerability via Data-Driven Detection of Synthetic Lethality , 2014, Cell.

[23]  Sourav Bandyopadhyay,et al.  Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer , 2014, Proceedings of the National Academy of Sciences.

[24]  P. Vandenabeele,et al.  Regulated necrosis: the expanding network of non-apoptotic cell death pathways , 2014, Nature Reviews Molecular Cell Biology.

[25]  Erinna F. Lee,et al.  Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53 , 2014, Genes & development.

[26]  Ling-gang Wu,et al.  Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis , 2013, Nature Cell Biology.

[27]  P. Johnston,et al.  Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.

[28]  K. Vousden,et al.  Interaction of p53 with the CCT Complex Promotes Protein Folding and Wild-Type p53 Activity , 2013, Molecular cell.

[29]  K. Shokat,et al.  Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers , 2013, Proceedings of the National Academy of Sciences.

[30]  A. Safa Roles of c-FLIP in Apoptosis, Necroptosis, and Autophagy , 2013, Journal of carcinogenesis & mutagenesis.

[31]  David R McIlwain,et al.  Caspase functions in cell death and disease. , 2013, Cold Spring Harbor perspectives in biology.

[32]  Travis J Cohoon,et al.  Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. , 2013, Cancer cell.

[33]  T. Akihisa,et al.  Kuguaglycoside C, a constituent of Momordica charantia, induces caspase‐independent cell death of neuroblastoma cells , 2012, Cancer science.

[34]  J. Utikal,et al.  Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.

[35]  M. MacFarlane,et al.  The 'complexities' of life and death: death receptor signalling platforms. , 2012, Experimental cell research.

[36]  Sven Diederichs,et al.  The hallmarks of cancer , 2012, RNA biology.

[37]  R. Medema,et al.  Checkpoint control and cancer , 2012, Oncogene.

[38]  G. McArthur,et al.  Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells , 2012, Oncogene.

[39]  Mari Mino-Kenudson,et al.  EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. , 2012, Cancer discovery.

[40]  R. Bernards,et al.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.

[41]  M. Barbacid,et al.  Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors , 2011, Nature Structural &Molecular Biology.

[42]  D. Green,et al.  RIPK-dependent necrosis and its regulation by caspases: a mystery in five acts. , 2011, Molecular cell.

[43]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[44]  Xiangwei Wu,et al.  Lung-Cancer Chemoprevention by Induction of Synthetic Lethality in Mutant KRAS Premalignant Cells In Vitro and In Vivo , 2011, Cancer Prevention Research.

[45]  I. Endo,et al.  The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells , 2011, Leukemia.

[46]  S. Susin,et al.  AIF‐mediated caspase‐independent necroptosis: A new chance for targeted therapeutics , 2011, IUBMB life.

[47]  M. Peter,et al.  Programmed cell death: Apoptosis meets necrosis , 2011, Nature.

[48]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[49]  R. Hakem,et al.  RIP3 mediates the embryonic lethality of caspase-8-deficient mice , 2011, Nature.

[50]  Guy S. Salvesen,et al.  Catalytic activity of the caspase-8-FLIPL complex inhibits RIPK3-dependent necrosis , 2011, Nature.

[51]  D. Green,et al.  Cell survival in tough times: The mitochondrial recovery plan , 2010, Cell cycle.

[52]  P. Vandenabeele,et al.  Molecular mechanisms of necroptosis: an ordered cellular explosion , 2010, Nature Reviews Molecular Cell Biology.

[53]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[54]  Hong Liu,et al.  Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase , 2010, Proceedings of the National Academy of Sciences.

[55]  Q. She,et al.  4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. , 2010, Cancer cell.

[56]  D. Livingston,et al.  BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. , 2010, Carcinogenesis.

[57]  T. Vanden Berghe,et al.  The Role of the Kinases RIP1 and RIP3 in TNF-Induced Necrosis , 2010, Science Signaling.

[58]  D. Silver,et al.  Synthetic lethality--a new direction in cancer-drug development. , 2009, The New England journal of medicine.

[59]  Christoph Borner,et al.  XIAP discriminates between type I and type II FAS-induced apoptosis , 2009, Nature.

[60]  P. Vandenabeele,et al.  RIP Kinases at the Crossroads of Cell Death and Survival , 2009, Cell.

[61]  F. Chan,et al.  Phosphorylation-Driven Assembly of the RIP1-RIP3 Complex Regulates Programmed Necrosis and Virus-Induced Inflammation , 2009, Cell.

[62]  G. Salvesen,et al.  Human Caspases: Activation, Specificity, and Regulation* , 2009, The Journal of Biological Chemistry.

[63]  P. Sorger,et al.  Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis , 2009, Nature.

[64]  K. Kinzler,et al.  A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53 , 2009, Proceedings of the National Academy of Sciences.

[65]  L. Galluzzi,et al.  Necroptosis: A Specialized Pathway of Programmed Necrosis , 2008, Cell.

[66]  T. Kuwana,et al.  Mechanism of apoptosis induction by inhibition of the anti-apoptotic BCL-2 proteins , 2008, Proceedings of the National Academy of Sciences.

[67]  Lisa S. Chen,et al.  Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. , 2008, Blood.

[68]  John Calvin Reed,et al.  Bcl-2 family proteins and cancer , 2008, Oncogene.

[69]  Elizabeth Iorns,et al.  A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor , 2008, The EMBO journal.

[70]  Alexei Degterev,et al.  Identification of RIP1 kinase as a specific cellular target of necrostatins. , 2008, Nature chemical biology.

[71]  D. Green,et al.  How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? , 2008, Trends in cell biology.

[72]  A. Letai,et al.  Diagnosing and exploiting cancer's addiction to blocks in apoptosis , 2008, Nature Reviews Cancer.

[73]  M. Ranson,et al.  X-linked inhibitor of apoptosis protein as a therapeutic target , 2007, Expert opinion on therapeutic targets.

[74]  A. Tward,et al.  Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC , 2007, Nature Medicine.

[75]  S. Elmore Apoptosis: A Review of Programmed Cell Death , 2007, Toxicologic pathology.

[76]  Michael Peyton,et al.  Synthetic lethal screen identification of chemosensitizer loci in cancer cells , 2007, Nature.

[77]  Michael B Yaffe,et al.  p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. , 2007, Cancer cell.

[78]  T. Jacks,et al.  Restoration of p53 function leads to tumour regression in vivo , 2007, Nature.

[79]  Carlos Cordon-Cardo,et al.  Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas , 2007, Nature.

[80]  W. Kaelin The Concept of Synthetic Lethality in the Context of Anticancer Therapy , 2005, Nature Reviews Cancer.

[81]  Alexei Degterev,et al.  Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury , 2005, Nature chemical biology.

[82]  Xiao-Ming Yin,et al.  Deletion of Bid impedes cell proliferation and hepatic carcinogenesis. , 2005, The American journal of pathology.

[83]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[84]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.

[85]  J. E. Duque-Parra Note on the origin and history of the term "apoptosis". , 2005, Anatomical record. Part B, New anatomist.

[86]  A. Ashworth,et al.  Hallmarks of 'BRCAness' in sporadic cancers , 2004, Nature Reviews Cancer.

[87]  Marc Nasoff,et al.  Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. , 2004, Cancer cell.

[88]  R. Wooster,et al.  Breast and ovarian cancer. , 2003, The New England journal of medicine.

[89]  Jiri Bartek,et al.  Chk1 and Chk2 kinases in checkpoint control and cancer. , 2003, Cancer cell.

[90]  Y. Shiloh ATM and related protein kinases: safeguarding genome integrity , 2003, Nature Reviews Cancer.

[91]  Xin Lu,et al.  Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.

[92]  R. Pierce,et al.  Bcl-2 expression inhibits liver carcinogenesis and delays the development of proliferating foci. , 2002, The American journal of pathology.

[93]  G. Cohen,et al.  The Apaf-1 apoptosome: a large caspase-activating complex. , 2002, Biochimie.

[94]  Ashok R Venkitaraman,et al.  Cancer Susceptibility and the Functions of BRCA1 and BRCA2 , 2002, Cell.

[95]  Jun Yu Li,et al.  Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. , 2001, Cancer research.

[96]  T. Mak,et al.  Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death , 2001, Nature.

[97]  Brian Seed,et al.  Fas triggers an alternative, caspase-8–independent cell death pathway using the kinase RIP as effector molecule , 2000, Nature Immunology.

[98]  S. Elledge,et al.  The DNA damage response: putting checkpoints in perspective , 2000, Nature.

[99]  John Savill,et al.  Corpse clearance defines the meaning of cell death , 2000, Nature.

[100]  G. Häcker The morphology of apoptosis , 2000, Cell and Tissue Research.

[101]  Ruedi Aebersold,et al.  Molecular characterization of mitochondrial apoptosis-inducing factor , 1999, Nature.

[102]  Y. Lazebnik,et al.  Caspases: enemies within. , 1998, Science.

[103]  Xiaodong Wang,et al.  Bid, a Bcl2 Interacting Protein, Mediates Cytochrome c Release from Mitochondria in Response to Activation of Cell Surface Death Receptors , 1998, Cell.

[104]  S. Korsmeyer,et al.  Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. , 1998, Blood.

[105]  M. Peter,et al.  Two CD95 (APO‐1/Fas) signaling pathways , 1998, The EMBO journal.

[106]  R E Burke,et al.  Apoptosis in neurodegenerative disorders. , 1997, Current opinion in neurology.

[107]  J C Reed,et al.  Somatic Frameshift Mutations in the BAX Gene in Colon Cancers of the Microsatellite Mutator Phenotype , 1997, Science.

[108]  C. Kitanaka,et al.  Apoptosis in cancer. , 1996, Human cell.

[109]  E. Sausville,et al.  UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. , 1996, Journal of the National Cancer Institute.

[110]  M. Raff,et al.  The Role of Apoptosis in Development, Tissue Homeostasis and Malignancy , 1995, Springer Netherlands.

[111]  Y. Tsujimoto,et al.  Involvement of the bcl-2 gene in human follicular lymphoma. , 1985, Science.

[112]  P. Nowell,et al.  Clustering of breakpoints on chromosome 11 in human B-cell neoplasms with the t(11 ; 14) chromosome translocation , 1985, Nature.

[113]  S. Kaye,et al.  PARP inhibitors: the race is on. , 2016, British journal of cancer.

[114]  D. Green,et al.  Molecular Cell Biology of Apoptosis and Necroptosis in Cancer. , 2016, Advances in experimental medicine and biology.

[115]  Lucio Crinò,et al.  Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. , 2013, The Lancet. Oncology.

[116]  R. Mohammad,et al.  Small-molecule inhibitors of Bcl-2 family proteins as therapeutic agents in cancer. , 2008, Recent patents on anti-cancer drug discovery.

[117]  S. Mariathasan,et al.  Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation , 2007, Nature Reviews Immunology.